What are the main side effects of bempedoic acid?

The ones that stand out are a rise in uric acid that can trigger gout, and a labeled warning about tendon rupture. It can also nudge up liver enzymes and creatinine, though the creatinine change does not mean kidney damage, and there is a small increase in gallstones. Most people tolerate it well, but these deserve a conversation, above all if you have gout.

Can I take bempedoic acid with ezetimibe?

Yes, and the two are sold together as a single pill called Nexlizet. Ezetimibe lowers cholesterol by a different mechanism, blocking absorption in the gut, so combining them lowers LDL more than either alone, by around 38%. For a statin-intolerant person who needs a larger drop, the combination is often the more useful choice.

What are the main side effects of bempedoic acid?

The ones that stand out are a rise in uric acid that can trigger gout, and a labeled warning about tendon rupture. It can also nudge up liver enzymes and creatinine, though the creatinine change does not mean kidney damage, and there is a small increase in gallstones. Most people tolerate it well, but these deserve a conversation, above all if you have gout.

Can I take bempedoic acid with ezetimibe?

Yes, and the two are sold together as a single pill called Nexlizet. Ezetimibe lowers cholesterol by a different mechanism, blocking absorption in the gut, so combining them lowers LDL more than either alone, by around 38%. For a statin-intolerant person who needs a larger drop, the combination is often the more useful choice.

Bempedoic Acid (Nexletol): For Statin-Intolerant Cholesterol | Philadelphia

TL;DR30-second take

Bempedoic acid (brand name Nexletol) is a once-daily 180 mg pill that lowers LDL cholesterol, designed for people who cannot tolerate statins. It works one step upstream of statins in the same pathway, but because it is activated in the liver but not in muscle, it rarely causes the muscle aches that drive people off statins. It lowers LDL by about 20% on its own, and more when paired with ezetimibe. Its standout feature is proof: in a large trial of statin-intolerant patients, it lowered the rate of heart attacks and artery procedures. The trade-offs are that its LDL-lowering is milder than a statin or a PCSK9 inhibitor, and it can raise uric acid and trigger gout. It is best seen as an option for the statin-intolerant rather than a first-line replacement for a statin you tolerate.

TL;DR: Bempedoic acid, sold as Nexletol, is a once-daily pill for lowering LDL cholesterol in people who cannot tolerate statins. It works one step upstream of statins, but because it is switched on in the liver and not in muscle, it rarely causes muscle aches. Its LDL-lowering is moderate, about 20% alone and about 38% combined with ezetimibe, milder than a strong statin or a PCSK9 inhibitor. Its main strength is proof: in a large trial of statin-intolerant patients, it lowered heart attacks and artery procedures, though not stroke or death. The main cautions are a rise in uric acid that can trigger gout, and a tendon-rupture warning. It is best used for the statin-intolerant, rather than as a first-line replacement for a statin you tolerate.

What is bempedoic acid, and how is it different from a statin?

Bempedoic acid, sold as Nexletol, is an oral cholesterol-lowering drug that works in the same cholesterol-making pathway as a statin, one step above it. Statins block an enzyme called HMG-CoA reductase; bempedoic acid blocks an enzyme just upstream, called ATP-citrate lyase. The net effect is similar, less cholesterol made in the liver and more LDL pulled out of the blood.

The clever part is what makes it gentler on muscle. Bempedoic acid is a prodrug, meaning it arrives inactive and has to be switched on by an enzyme inside your cells. That activating enzyme is present in the liver but absent in muscle.² So the drug does its cholesterol work in the liver, while your muscles never turn it on, which is the reason it rarely causes the muscle aches that lead so many people to quit statins. For someone whose main barrier to a statin is muscle symptoms, that difference is the whole point.

Does it lower heart attack risk?

This is where bempedoic acid earns its place, because it has something most non-statin cholesterol drugs lack: a large trial showing it lowers cardiovascular events, done in the very group that needs it. CLEAR Outcomes enrolled about 14,000 statin-intolerant people at high cardiovascular risk and followed them for more than three years.¹ Bempedoic acid lowered the main composite of heart problems by 13% compared with placebo. The benefit was clearest for heart attacks, down about 23%, and for artery-opening procedures, down about 19%.

Two boundaries belong on that result. The stroke part of the composite did not reach significance on its own, and the trial did not show a reduction in cardiovascular death or in death from any cause. So the fair claim is that bempedoic acid prevents heart attacks and procedures in statin-intolerant people, and the evidence does not stretch to preventing death. That is still a meaningful result for a group that has often been left without a proven option.

How much does it lower cholesterol?

On its own, bempedoic acid lowers LDL cholesterol by roughly 20%.¹ That is useful, but it is milder than a strong statin, which can lower LDL by 40 to 50%, and milder than a PCSK9 inhibitor. Paired with ezetimibe in a single combination pill, sold as Nexlizet, the two together lower LDL by around 38%, which closes much of the gap.³

The practical read is that bempedoic acid is a moderate-strength tool. For a person who needs a small-to-moderate additional drop in LDL or ApoB and cannot take a statin, it can do the job, sometimes better when combined with ezetimibe. For someone who needs their LDL cut in half, it is usually not enough on its own.

Who is bempedoic acid for?

The clearest fit is a statin-intolerant person who still needs to lower LDL and cardiovascular risk. Statin intolerance is common, and often centers on muscle aches, though a careful look shows that a good share of those symptoms also occur on placebo, so the first step is usually a thoughtful attempt to find a statin you tolerate before moving on. When that truly fails, bempedoic acid becomes a strong candidate, and it stands out as one of the few non-statin options with proof that it prevents cardiovascular events. First approved in 2020, bempedoic acid gained a broader FDA approval in 2024 for reducing cardiovascular risk, in both people who have had an event and people at high risk who have not.³

It is less suited as a first move for someone who has not tried a statin, or who tolerates one well. In those cases a statin remains the better-proven, cheaper foundation, with bempedoic acid held in reserve.

What are the side effects and cautions?

Bempedoic acid is generally well tolerated, but it has a few distinctive issues to know about.

Gout and uric acid. The most notable is that it raises uric acid, and can bring on gout in people prone to it. In the large trial, high uric acid and gout were clearly more common than on placebo. If you have a history of gout, mention it to your physician before starting.
Tendon problems. The label carries a warning about tendon rupture, so any new tendon pain during treatment should prompt a call to your doctor.
Lab changes. It can nudge up liver enzymes and creatinine. The creatinine rise looks alarming but reflects a change in how the kidney handles creatinine, not true kidney damage. A small increase in gallstones has also been seen.
Drug interactions. Bempedoic acid raises the blood levels of certain statins, so it is not combined with higher doses of simvastatin or pravastatin.

None of this is unusual for a cardiovascular drug; it just means the decision, and the monitoring, belong with a physician who knows your history.

Guidance from the Clinic

"For years, the frustrating gap in my toolkit was the patient who truly could not take a statin and was left with weaker options. Bempedoic acid helps fill that gap, and what I like most is that it was tested for whether it prevents heart attacks, in statin-intolerant people, and it does. I keep its limits in view too: it lowers cholesterol less than a statin, it can stir up gout, and it has not been shown to prevent death. So the way I use it is specific. If someone has failed a fair trial of statins and still needs to lower their risk, this is a strong, evidence-backed choice, often paired with ezetimibe. If someone has never given a statin a fair try, I start there, because it is still the most proven and the most affordable. It is a case-by-case decision, made with your history and your numbers in front of us."

Key Takeaways

Bempedoic acid (Nexletol) lowers LDL cholesterol by working one step upstream of statins, and because it is activated in the liver but not muscle, it rarely causes muscle aches.
In statin-intolerant patients, the CLEAR Outcomes trial showed a 13% drop in cardiovascular events, driven by fewer heart attacks and procedures, though not fewer strokes or deaths.
Its LDL-lowering is moderate, about 20% alone and about 38% combined with ezetimibe (sold as Nexlizet), milder than a strong statin or a PCSK9 inhibitor.
The main cautions are a rise in uric acid with gout risk, and a tendon-rupture warning, plus minor lab changes and a statin drug interaction.
It is best for people who cannot tolerate a statin, rather than a first-line replacement for a statin that works for you.

Beyond Statins: Other Ways to Lower Cholesterol and ApoB - the full menu of options
Nervous About Statins? - finding a statin you tolerate first
Inclisiran (Leqvio): The Twice-a-Year Cholesterol Shot - a stronger injectable option
ApoB and Heart Health - the particle count worth targeting
Ezetimibe (Zetia) - its partner in the Nexlizet combination pill
What Is a Preventive Cardiologist? - the decision layer around these choices

Scientific References

Nissen SE, Lincoff AM, Brennan D, et al. "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients." New England Journal of Medicine. 2023;388(15):1353-1364.
Pinkosky SL, Newton RS, Day EA, et al. "Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis." Nature Communications. 2016;7:13457.
U.S. Food and Drug Administration. Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) prescribing information, with the 2024 cardiovascular risk-reduction label expansion.

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Bempedoic acid, sold as Nexletol, is a once-daily pill that lowers LDL cholesterol. It works in the same pathway as statins but one step earlier, and because it is activated in the liver but not in muscle, it rarely causes the muscle aches that make many people stop statins. It is used mainly for people who cannot tolerate a statin and still need to lower their cholesterol and cardiovascular risk.

Not in strength. A statin lowers LDL more, is far cheaper, and has the deepest evidence base, so a statin you tolerate is still the first choice. Bempedoic acid's advantage is for people who cannot take a statin, above all because of muscle symptoms, since it rarely causes them. It also has its own trial showing it prevents heart attacks in that group, which sets it apart from most non-statin options.

Yes, in statin-intolerant people. A large trial called CLEAR Outcomes found it lowered the combined rate of cardiovascular events by 13%, driven mainly by fewer heart attacks and fewer artery procedures. It did not significantly reduce stroke or death, so the proven benefit is specifically about heart attacks and procedures. That still makes it one of the few non-statin cholesterol drugs with hard outcome evidence.

Deep-Dive Questions

It comes down to where the drug is switched on. Bempedoic acid is a prodrug, inactive until an enzyme converts it to its working form. That enzyme is present in the liver but not in skeletal muscle, so the liver activates the drug and lowers cholesterol while muscle tissue never does. Statins, by contrast, are active throughout the body, including in muscle, which is thought to underlie their muscle side effects. This liver-specific activation is the mechanistic reason bempedoic acid rarely causes the aches that lead people to stop statins.

Stronger than for most non-statin options, because it has a dedicated cardiovascular outcomes trial. CLEAR Outcomes randomized about 14,000 statin-intolerant patients and showed a 13% reduction in major cardiovascular events over more than three years. That is the kind of hard evidence, counting heart attacks rather than only cholesterol numbers, that many cholesterol drugs never generate. The clear limit is that the benefit was in heart attacks and procedures, rather than in stroke or death, and the LDL-lowering is moderate.

Think of it as a moderate-strength, muscle-friendly option that sits between the basics and the strongest agents. A statin is the foundation when tolerated. Ezetimibe is a mild add-on. The PCSK9 inhibitors and inclisiran are the strongest lowering tools. Bempedoic acid's niche is the statin-intolerant patient who needs proven risk reduction with a low chance of muscle symptoms, and it can be combined with ezetimibe for more lowering. The goal, as always, is getting ApoB and LDL to target by whatever combination you tolerate.

It is a reasonable thing to raise, but usually after a fair attempt to find a workable statin. Many people who believe they cannot take any statin turn out to tolerate a different one, a lower dose, or alternate-day dosing, and a careful rechallenge makes sense first because statins remain the most proven and cheapest option. If that has been done and statins still do not work for you, bempedoic acid is one of the best-supported next steps to discuss with your physician.

Ready when you are